8-K filed August 6, 2021, 7:59 PM ET ticker INDP CIK 0001857044

M&A confidence high sentiment neutral materiality 0.90

Indaptus Therapeutics completes reverse merger with Decoy Biosystems; begins trading as INDP on Nasdaq

Indaptus Therapeutics, Inc.

Decoy merger closed Aug 3, 2021; exchange ratio of 2.654353395 Indaptus shares per Decoy share.
Post-merger 5,405,963 shares outstanding; Decoy shareholders own 65.6%, Intec Israel owns 34.4%.
Company renamed Indaptus Therapeutics, now a pre-clinical biotech focused on cancer and viral immunotherapy.
Board expanded to eight directors; Michael Newman appointed Chief Scientific Officer; CEO Meckler remains.
Expected to dismiss PWC as auditor and engage Haskell & White for fiscal 2021 audit.

item 2.01 item 3.01 item 3.02 item 8.01 item 4.01 item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Brian O’Callaghan

Director

INDP · Indaptus Therapeutics, Inc.

Filed: August 6, 2021, 7:59 PM ET

each of Michael Newman, Ph.D., Hoonmo Lee and Brian O’Callaghan were appointed as directors of the Company.

Appointed

Michael Newman

Chief Scientific Officer

INDP · Indaptus Therapeutics, Inc.

Filed: August 6, 2021, 7:59 PM ET

Michael Newman, Ph.D. was appointed as Chief Scientific Officer.

Appointed

Hoonmo Lee

Director

INDP · Indaptus Therapeutics, Inc.

Filed: August 6, 2021, 7:59 PM ET

each of Michael Newman, Ph.D., Hoonmo Lee and Brian O’Callaghan were appointed as directors of the Company.

Appointed

Michael Newman

Director

INDP · Indaptus Therapeutics, Inc.

Filed: August 6, 2021, 7:59 PM ET

each of Michael Newman, Ph.D., Hoonmo Lee and Brian O’Callaghan were appointed as directors of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Brian O’Callaghan was appointed as Director at Indaptus Therapeutics, Inc..

Action: appointed
Role: Director

Exact text from the filing

each of Michael Newman, Ph.D., Hoonmo Lee and Brian O’Callaghan were appointed as directors of the Company.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Michael Newman was appointed as Chief Scientific Officer at Indaptus Therapeutics, Inc..

Action: appointed
Role: Chief Scientific Officer

Exact text from the filing

Michael Newman, Ph.D. was appointed as Chief Scientific Officer.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Hoonmo Lee was appointed as Director at Indaptus Therapeutics, Inc..

Action: appointed
Role: Director

Exact text from the filing

each of Michael Newman, Ph.D., Hoonmo Lee and Brian O’Callaghan were appointed as directors of the Company.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Michael Newman was appointed as Director at Indaptus Therapeutics, Inc..

Action: appointed
Role: Director

Exact text from the filing

each of Michael Newman, Ph.D., Hoonmo Lee and Brian O’Callaghan were appointed as directors of the Company.

View on SEC.gov

Indaptus Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-21-018937

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.